[go: up one dir, main page]

AR130403A2 - Composiciones de hialuronano con elasticidad alta y sus usos - Google Patents

Composiciones de hialuronano con elasticidad alta y sus usos

Info

Publication number
AR130403A2
AR130403A2 ARP230102360A ARP230102360A AR130403A2 AR 130403 A2 AR130403 A2 AR 130403A2 AR P230102360 A ARP230102360 A AR P230102360A AR P230102360 A ARP230102360 A AR P230102360A AR 130403 A2 AR130403 A2 AR 130403A2
Authority
AR
Argentina
Prior art keywords
composition
hyaluronan
pharmaceutically active
post
joint dysfunction
Prior art date
Application number
ARP230102360A
Other languages
English (en)
Inventor
Endre A Balazs
Carlos Belmonte
Original Assignee
Matrix Biology Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Biology Inst filed Critical Matrix Biology Inst
Publication of AR130403A2 publication Critical patent/AR130403A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica caracterizada porque comprende hialuronano, en donde: el hialuronano está presente en dicha composición en una concentración mayor de aproximadamente 30 mg/ml; el hialuronano tiene un peso molecular promedio de entre aproximadamente 1 y aproximadamente 2 millones; el hialuronano no está entrecruzado y/o está sustancialmente libre de modificaciones químicas; y en donde la composición está sustancialmente libre de otras sustancias farmacéuticamente activas. Reivindicación 2: La composición de la reivindicación 1, caracterizada porque la otra sustancia farmacéuticamente activa es una proteína. Reivindicación 3: La composición de la reivindicación 1, caracterizada porque la otra sustancia farmacéuticamente activa es un glicosaminoglicano que es diferente del hialuronano. Reivindicación 4: La composición de la reivindicación 1, caracterizada porque la otra sustancia farmacéuticamente activa es hidroxipropilmetilcelulosa. Reivindicación 6: La composición de la reivindicación 5, caracterizada porque el anestésico tópico es lidocaína o bupivacaína. Reivindicación 9: La composición de la reivindicación 8, caracterizada porque la solución amortiguadora es solución salina amortiguada con fosfato (PBS). Reivindicación 10: La composición de la reivindicación 1, caracterizada porque la composición tiene una elasticidad de al menos aproximadamente 200 Pascales cuando se mide a una frecuencia de 0,5 Hz. Reivindicación 28: Un método para reducir al menos un síntoma asociado con disfunción de la articulación, caracterizado porque comprende administrar a un sujeto que lo necesita una cantidad terapéuticamente eficaz de la composición de la reivindicación 1, reduciendo de este modo al menos un síntoma asociado con disfunción de la articulación. Reivindicación 29: El método de la reivindicación 28, caracterizado porque la disfunción de la articulación es dolor de articulación o disfunción de la articulación asociada con osteoartritis, post-artroscopia, post-ortoplastia, post-lesión o inmovilización prolongada. Reivindicación 39: Un dispositivo caracterizado porque comprende la composición de la reivindicación 1 o 14. Reivindicación 40: El dispositivo de la reivindicación 39, caracterizado porque el dispositivo es una jeringa precargada.
ARP230102360A 2013-07-10 2023-09-06 Composiciones de hialuronano con elasticidad alta y sus usos AR130403A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361844645P 2013-07-10 2013-07-10

Publications (1)

Publication Number Publication Date
AR130403A2 true AR130403A2 (es) 2024-12-04

Family

ID=51261252

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140102559A AR096875A1 (es) 2013-07-10 2014-07-10 Composiciones de hialuronano de gran elasticidad y sus usos
ARP230102360A AR130403A2 (es) 2013-07-10 2023-09-06 Composiciones de hialuronano con elasticidad alta y sus usos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140102559A AR096875A1 (es) 2013-07-10 2014-07-10 Composiciones de hialuronano de gran elasticidad y sus usos

Country Status (8)

Country Link
US (5) US9492474B2 (es)
EP (3) EP3019177B1 (es)
JP (5) JP6357228B2 (es)
AR (2) AR096875A1 (es)
ES (2) ES2933549T3 (es)
PL (2) PL3019177T3 (es)
PT (2) PT3613423T (es)
WO (1) WO2015006460A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2933549T3 (es) 2013-07-10 2023-02-10 Matrix Biology Inst Composiciones de hialuronano con alta elasticidad y usos de las mismas
CN108135926A (zh) * 2015-09-24 2018-06-08 基质生物研究所 高弹性透明质酸组合物及其使用方法
EP4368217A3 (en) 2018-01-10 2024-07-31 The Provost, Fellows, Scholars and other Members of Board of Trinity College Dublin System and methods for sealing a channel in tissue
WO2020144372A1 (en) 2019-01-10 2020-07-16 The Provost, Fellows, Scholars And Other Members Of Board Of Trinity College Dublin Composite viscoelastic hydrogel, and uses thereof for sealing a channel in tissue
EP3781175A1 (en) 2018-04-18 2021-02-24 i.com Medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
WO2020157570A1 (en) 2019-01-31 2020-08-06 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
WO2020232539A1 (en) 2019-05-17 2020-11-26 The Governing Council Of The University Of Toronto Sustained release local anesthetic hydrogel composition

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4517295A (en) 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
FR2553099B1 (fr) 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
AU620821B2 (en) 1987-08-25 1992-02-27 Macnaught Pty Limited Hyaluronic acid lubricating compounds
US5403592A (en) 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
DE69017559T3 (de) * 1989-07-24 2002-06-06 Allergan Pharmaceuticals (Ireland) Ltd., Irvine Stabile Lösung von Hyaluronat in einem isotonen Salzmilieu.
CA2060223C (en) 1991-02-12 1999-07-20 Clarence C. Lee Injectable medical lubricating fluid composition and method of use
US5234914A (en) 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
AU682670B2 (en) 1993-02-05 1997-10-16 Becton Dickinson & Company Syringe needle isolation device
US5679655A (en) 1993-08-04 1997-10-21 Patent Biopharmaceutics, Inc. Method of treating lesions resulting from genital herpes with hyaluronic acid-urea pharmaceutical compositions
US5607400A (en) 1995-05-19 1997-03-04 Becton, Dickinson And Company Pre-fillable syringe and stopper assembly therefor
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JPH09173450A (ja) 1995-12-26 1997-07-08 Nissho Corp プレフィルドシリンジ
JP3293122B2 (ja) 1996-12-13 2002-06-17 ニプロ株式会社 プレフィルドシリンジ
SE9700827D0 (sv) 1997-03-07 1997-03-07 Pharmacia & Upjohn Ab Ophthalmic composition
RU2126669C1 (ru) 1997-04-25 1999-02-27 Новокузнецкий государственный институт усовершенствования врачей Способ лечения синдрома сухого глаза
SE9703425D0 (sv) 1997-09-23 1997-09-23 Pharmacia & Upjohn Ab Prefilled ampooules and manufacture thereof
DE19751219A1 (de) 1997-11-19 1999-05-27 Vetter & Co Apotheker Spritze, insbesondere vorgefüllte Spritze, oder Karpule
AU3001399A (en) 1998-03-13 1999-09-27 Becton Dickinson & Company Method for assembling and packaging medical devices
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
JP3591636B2 (ja) 2000-04-03 2004-11-24 ニプロ株式会社 プレフィルドシリンジ
DK1142566T3 (da) 2000-04-07 2004-02-09 Medidom Lab Oftalmologiske formuleringer på basis af ciclosporin, hyaluronsyre og polysorbat
US7635489B2 (en) 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
JP2003119147A (ja) * 2001-10-10 2003-04-23 Raku:Kk ヒアルロン酸化合物の水溶液組成物
US20030133986A1 (en) 2001-11-21 2003-07-17 Fu-Pao Tsao Compositions for stabilizing poly (carboxylic acids)
US7820194B2 (en) 2001-12-21 2010-10-26 Alcon, Inc. Combinations of viscoelastics for use during surgery
JP4141156B2 (ja) 2002-03-15 2008-08-27 日本ベクトン・ディッキンソン株式会社 プランジャ後退制限機構付きプレフィルドシリンジ
ATE552873T1 (de) 2002-07-02 2012-04-15 Terumo Corp Spritze und vorgefüllte spritze
CN1671400A (zh) 2002-07-03 2005-09-21 派瑞克科学公司 透明质酸组合物以及使用方法
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
DE10254321A1 (de) 2002-11-21 2004-06-17 Arzneimittel Gmbh Apotheker Vetter & Co. Ravensburg Vorgefüllte Spritze
JP2004229750A (ja) 2003-01-28 2004-08-19 Nipro Corp プレフィルドシリンジ及びそのバレルの製造方法
US20040167480A1 (en) * 2003-02-21 2004-08-26 Advanced Medical Optics, Inc. Administration of multiple viscoelastic solutions with a multi-compartment syringe
JP2004262777A (ja) 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US20050075611A1 (en) 2003-10-01 2005-04-07 Hetzler Kevin G. Low extractable, thermoplastic syringe and tip cap
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
WO2005110439A2 (en) 2004-05-07 2005-11-24 S.K. Pharmaceuticals, Inc. Stabilized hyaluronan preparations and related methods
US8372814B2 (en) 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
WO2006067608A1 (en) 2004-12-22 2006-06-29 Laboratoire Medidom S.A. Aqueous formulations based on sodium hyaluronate for parenteral use
CA2744999A1 (en) 2004-12-30 2006-07-13 Genzyme Corporation Regimens for intra-articular viscosupplementation
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
US8388995B1 (en) 2006-02-03 2013-03-05 Auburn University Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform
ITPD20050056A1 (it) 2005-03-02 2006-09-03 Fidia Farmaceutici Derivati ammidici del'acido ialuronico in osteoartrosi
US7767710B2 (en) 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
DE102005055275A1 (de) 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
ATE494308T1 (de) * 2005-11-22 2011-01-15 Centre Nat Rech Scient Neue derivate von hyaluronsäure, herstellungsverfahren dafür und verwendungen davon
US7988675B2 (en) 2005-12-08 2011-08-02 West Pharmaceutical Services Of Delaware, Inc. Automatic injection and retraction devices for use with pre-filled syringe cartridges
EP1968614A2 (en) 2005-12-14 2008-09-17 Anika Therapeutics Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
JP4682850B2 (ja) 2006-01-12 2011-05-11 ニプロ株式会社 プレフィルドシリンジ
AU2007208054A1 (en) 2006-01-25 2007-08-02 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
US7674781B2 (en) 2006-04-28 2010-03-09 Heather Sheardown Hyaluronic acid-retaining polymers
AR062046A1 (es) 2006-07-25 2008-08-10 Osmotica Pharmaceutical Argentina S A Soluciones oftalmicas
EP2059206B8 (en) 2006-08-28 2012-07-11 Rexaderm, Inc. Dry wound dressing and drug delivery system
ITMI20061668A1 (it) * 2006-09-01 2008-03-02 Schiena Michele Giuseppe Di Composizione a base di acido ialuronico e suoi sali per il trattamento di lesioni epiteliali
EP2087020A4 (en) 2006-11-17 2010-11-24 Agency Science Tech & Res POROUS POLYMERIC MATERIAL COMPRISING A CROSS-LINING AGENT
EP1994934A4 (en) 2006-12-05 2010-03-10 Glycoscience Lab Inc THERAPEUTIC AGENT AGAINST DEGENERATIVE ARTHRITIS
FR2918276B1 (fr) 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
WO2009111159A2 (en) 2008-03-03 2009-09-11 New York University Biocompatible materials containing stable complexes of tsg-6 and hyaluronan and method of using same
WO2009122541A1 (ja) * 2008-03-31 2009-10-08 Inui Hiroaki ヒト胚の体外受精及び培養用培養液及びヒト胚の体外受精及び培養方法
EP2281008B1 (en) 2008-04-04 2017-01-04 University of Utah Research Foundation Alkylated and sulfated hyaluronan compounds, methods for their preparation and use thereof
FR2938187B1 (fr) 2008-11-07 2012-08-17 Anteis Sa Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur
US9072779B2 (en) * 2009-01-07 2015-07-07 Robert John Petrella Treatment of soft tissue injury using hyaluronic acid and botulinum toxin
US20100178317A1 (en) 2009-01-09 2010-07-15 Burke Susan E Lens Care Solutions with Hyaluronic Acid
US8979821B2 (en) 2009-04-14 2015-03-17 Fezza Family Properties, Llc Lacrimal filler
US20100303915A1 (en) 2009-06-02 2010-12-02 Abbott Medical Optics Inc. Therapeutic opthalmic emulsions
RU2538696C2 (ru) 2009-06-05 2015-01-10 Эдвард Так ВЭЙ Лечение дискомфорта глаз путем местного применения охлаждающего агента на наружной поверхности века
US20110071630A1 (en) 2009-09-10 2011-03-24 Boston Foundation For Sight Sodium channel blocker delivery system with scleral lens
CN102781463A (zh) 2009-10-07 2012-11-14 戈诺珍公司 用于皮肤再生的方法和组合物
US20110171310A1 (en) 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
CA2794254C (en) 2010-03-22 2018-09-04 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US20130209531A1 (en) 2010-06-08 2013-08-15 University Of Utah Research Foundation Applications of partially and fully sulfated hyaluronan
WO2012027834A1 (en) 2010-09-02 2012-03-08 Mcmaster University Hyaluronic acid-containing biopolymers
AU2011299851A1 (en) 2010-09-10 2013-04-04 Santen Pharmaceutical Co., Ltd. Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist with hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US20140038917A1 (en) 2011-04-19 2014-02-06 Anteis S.A. Sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint
GB201118586D0 (en) 2011-10-27 2011-12-07 Turzi Antoine New A-PRP medical device, manufacturing machine and process
EP2596796B1 (en) 2011-11-24 2013-11-13 Quimera Ingenieria Biomedica, S.L. Complex obtained from hyaluronic acid or a salt thereof and chondroitin sulphate mixtures
EP2818172A4 (en) 2012-02-22 2016-02-17 Hyaluronan Res Inst Inc TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
US20150037422A1 (en) 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
UA113434C2 (uk) 2012-05-04 2017-01-25 Алкон Рісерч, Лтд. Офтальмологічна композиція з поліпшеним захистом від зневоднювання й утриманням
FR2991876B1 (fr) 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
CN111419794A (zh) 2013-02-01 2020-07-17 阿勒根公司 包含透明质酸钠和羧甲基纤维素的人工泪液
US9226938B2 (en) 2013-03-14 2016-01-05 RMG Rehabilitation Management Group, LP Combinatorial therapy for treatment of osteoarthritis of the knee
WO2014156939A1 (ja) 2013-03-25 2014-10-02 国立大学法人東京農工大学 植物の栽培方法
ITMI20130883A1 (it) 2013-05-30 2014-12-01 Eurores S R L Composizioni farmaceutiche comprendenti collagene e sodio ialuronato
ES2933549T3 (es) 2013-07-10 2023-02-10 Matrix Biology Inst Composiciones de hialuronano con alta elasticidad y usos de las mismas
ES2784229T3 (es) 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
AU2014352672B2 (en) 2013-11-25 2018-11-29 Deuteria Biomaterials, Llc Deuterium-enriched hyaluronan
FR3015290B1 (fr) 2013-12-23 2017-01-13 Lab Vivacy Compositions d'acide hyaluronique compreant de la mepivacaine
CN108135926A (zh) 2015-09-24 2018-06-08 基质生物研究所 高弹性透明质酸组合物及其使用方法

Also Published As

Publication number Publication date
JP2018138622A (ja) 2018-09-06
PT3019177T (pt) 2020-12-30
ES2837626T3 (es) 2021-07-01
US10383890B2 (en) 2019-08-20
PT3613423T (pt) 2022-12-07
AR096875A1 (es) 2016-02-03
US20170071974A1 (en) 2017-03-16
US20200030363A1 (en) 2020-01-30
US20150018303A1 (en) 2015-01-15
JP2024028669A (ja) 2024-03-04
EP3613423B1 (en) 2022-10-26
JP7025039B2 (ja) 2022-02-24
PL3613423T3 (pl) 2023-02-13
US9492474B2 (en) 2016-11-15
US10933085B2 (en) 2021-03-02
ES2933549T3 (es) 2023-02-10
JP6598929B2 (ja) 2019-10-30
PL3019177T3 (pl) 2021-04-19
EP3019177B1 (en) 2020-11-04
US20250352572A1 (en) 2025-11-20
EP3613423A1 (en) 2020-02-26
JP2016526573A (ja) 2016-09-05
US11524027B2 (en) 2022-12-13
JP6357228B2 (ja) 2018-07-11
US20210161947A1 (en) 2021-06-03
WO2015006460A1 (en) 2015-01-15
EP4137139A1 (en) 2023-02-22
EP3019177A1 (en) 2016-05-18
JP2019214632A (ja) 2019-12-19
JP2022058871A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
AR130403A2 (es) Composiciones de hialuronano con elasticidad alta y sus usos
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
BR112022013150A2 (pt) Derivado da insulina
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
MX389346B (es) Formulaciones de anticuerpos monoclonales de alta concentración.
RU2020123728A (ru) Композиции гиалуроновой кислоты с высокоэластичными свойствами и способы их применения
HRP20240485T1 (hr) Pripravci glp-1 i njihova upotreba
BR112015027555A2 (pt) dispositivos médicos que incluem adaptador de frasco com módulo de fármaco seco em linha
BR112012019549A2 (pt) reservatório para uso em um módulo medicamentoso, módulo medicamentoso que compreende esse reservatório e dispositivo de entrega de fármaco.
BR112014026718A2 (pt) variantes ctla-4
MX2009000812A (es) Soluciones de metotrexato concentradas.
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
RU2011121612A (ru) Инъекционная композиция полидезоксирибонуклеотидов для лечения костно-суставных заболеваний
AR112482A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry
EP4606430A3 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
EA201201617A1 (ru) Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
TWI612965B (zh) 玻尿酸之用途及疼痛抑制用醫藥組成物
CY1113683T1 (el) Συστημα συσκευασιας για φαρμακευτικες συνθεσεις και kit για ενδοφλεβια χορηγηση
MX2009013183A (es) Uso de la proteina de fusion taci-ig, tal como atacicept, para la elaboracion de un medicamento para tratar lupus eritematoso.
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas
RU2012100621A (ru) Композиция для инъекций, содержащая гидроксихлорохин, для местного применения при лечении геморроя
MX373378B (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.